CHANGING PARDIGMS IN BREAST SURGERY

Slides:



Advertisements
Similar presentations
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Advertisements

Breast Cancer. Introduction Most common female cancer Accounts for 32% of all female cancer 211,300 new cases yearly and rising 40,000 deaths yearly.
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
DCIS – Are we cutting it? Dr Alex Lemaigre With thanks to:
Breast Cancer in Pregnancy
Giuliano Pre-SSO mins ASCO Z mins
Departments - Surgery - Gerontology and Geriatrics Department of SurgeryDepartment of Gerontology & Geriatrics Prof. dr. C.J.H. van de VeldeProf. dr. R.G.J.
Breast cancer surgery Breast preserving and oncoplastic surgery (2)
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Hon-chi Yip Department of Surgery North District Hospital.
Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
Radiotherapy in Carcinoma of the Breast Patrick S Swift, MD Director, Radiation Oncology Alta Bates Comprehensive Cancer Center Berkeley, CA.
Breast Cancer Surgery: Can I still keep my breast? Yip Cheng Har Professor Dept of Surgery UMMC.
“Conservative mastectomy” the nipple sparing tecnique Alberto Luini Senology Division European instiute of Oncology-Milan.
Breast Conservation Surgery
Margins: less is just as good
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.
West Midlands Cancer Intelligence Unit NHSBSP Surgical QA Data for the Year of Screening 1 April 2002 to 31 March 2003 Dr Gill Lawrence and Professor Jan.
Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.
Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.
Breast Cancer - the Evidence for Current Management
Elshami M.Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS, USA
Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.
William A. Barber, M.D. Piedmont Hospital
How are we doing? Quality in Breast Cancer Care Dr Michelle Goecke Surgical Oncology Network Update October 18, 2014.
BCT: Towards Optimal Outcomes
Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD.
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #1 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.
Breast Cancer: The Profile Ma. Belen E. Tamayo,M.D. Medical Oncologist Makati Medical Center The Medical City.
Management of DCIS KWH Experience Dr. Carmen Ho.
Radiation Breast Oncology Highlights of SABC 2006 Alison Bevan, MD PhD UCSF Radiation Oncology January, 2007.
Ductal Carcinoma In Situ Shahla Masood, M.D. Professor of Pathology University of Florida College of Medicine - Jacksonville Chief of Pathology and Laboratory.
BREAST MRI IN RADIATION THERAPY PLANNING MARSHA HALEY, M.D. ASSISTANT PROFESSOR UNIVERSITY OF PITTSBURGH CANCER INSTITUTE PITTSBURGH, PENNSYLVANIA, USA.
Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer Krag DN et al. Proc ASCO 2010;Abstract LBA505.
Evidence Based For invasive breast cancer BCT is Tumor excision, axillary node dissection, whole breast radiation Modified mastectomy is total mastectomy.
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.
TREATMENT Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical.
Quantifying the Morbidity of the Unplanned Sarcoma Excision
1789 patients, 1982 – 1989, premenopausal, node + or Tumor > 5cm, M0 Total mastectomy, level I + II (partly) + CMF +/- 50Gy/25fx (electrons + photons)
Radical Mastectomy is no longer the standard Improved adjuvant and neoadjuvant therapy Chemotherapy Endocrine therapy Radiation treatment Reconstruction.
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,
Neoadjuvant SystemicTreatment Strategies for Breast Cancer Donald W. Northfelt, MD, FACP Professor of Medicine Mayo Clinic College of Medicine Associate.
Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.
Baselga J et al. Proc SABCS 2010;Abstract S3-3.
Basingstoke Colorectal The Particular Problem of Low Rectal Cancer Brendan Moran Basingstoke 4 th East-West Colorectal Days Hungary 2008.
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
Annals of Oncology 24: 2206–2223, 2013 R3 조영학
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
The impact of age on outcome in early-stage breast cancer 방사선종양학과 R2. 최진현.
PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,
The New trends in the Management of Breast Cancer 謝渙發 桃園縣醫師公會監事 怡仁綜合醫院副院長 教育部部定助理教授 國防醫學院外科學系臨床教授.
Overview: Breast Cancer- Surgical Treatment
Nicolas Ajkay, MD, FACS Assistant Professor of Surgery
Operative Approach and
Dr Amit Gupta Associate Professor Dept Of Surgery
Breast conserving surgery (BCT): Every millimetre counts
Surgical Management of the Breast in Breast Cancer
Single center experiences with intraoperative radiotherapy (IORT) as a boost during oncoplastic breast-conserving surgery Malter W¹, Puppe J¹, Rogée K¹,
THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.
SPECIMEN SONOGRAM - Procedure
徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2
DISSERTATION PRINCIPAL INVESTIGATOR: Dr Vijay Kumar Sharma
THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018
Prognosis of angiosarcoma at different anatomic sites
Breast Conservation Therapy
Presentation transcript:

CHANGING PARDIGMS IN BREAST SURGERY Dr S Sahni Senior Consultant Breast Surgeon Indraprastha Apollo Hospital

New Paradigms From To Anatomical concept of cancer spread Aggressive radio-surgery To Biological concept of cancer spread Targeted conservative treatments Dr S.R.Sahni,2008

MASTECTOMY vs CONSERVATION

INDICATIONS FOR MASTECTOMY Inability to obtain radiation therapy Multicentricity Multifocality Large operable cancers , unfit for radiation ?BRCAness Skin involvement

ARE THESE ABSOLUTE OR OBSELETE?………

DEFINITIONS Multicentricity- Two or more foci of cancer in different quadrants of the same breast Multifocality- two or more foci of cancer in the same breast quadrant

T Margin positivity is conditioned by the extent of breast resection. 57% 40% 16% CASES T 1 2 3 CM. >40% of specimen showed invasive foci at >2cm from the primary Holland 1985

TRADITIONAL PARADIGM Multicentric (MC) & Multifocal(MF) Breast Cancer are regularly considered a relative contraindication for Breast Conserving Therapy (BCT)

THE REASONING Perceived higher risk for in-breast recurrence since it is assumed that in MF/MC cancer the risk of more invasive foci in the breast is greater and radiotherapy less effective Bad cosmetic results –wider excisions/ multiple wide excisions and larger boost volumes with more fibrosis

MRI The use of MRI is associated with increased Mastectomy rates. Most Likely due to extra findings: considered to be MC or MF disease Houssami N, Morrow M et al Pre-operative magnetic resonance imaging in breast cancer:meta analysis of surgical outcomes. Ann Surg. 2013

THE EVIDENCE ? Is MF/MC disease associated with worse disease free and overall survival? Is BCT in MF/MC disease associated with higher local relapse rates?

Multicentric (MC) & Multifocal(MF) Breast Cancer are regularly considered a relative contraindication for Breast Conserving Therapy (BCT)

Vera-Badillo et al Effect of multifocality and multicentricity on outcome in early stage breast cancer. BCRT. 2014 N= 67,557 22 studies 9.5% MF/MC

MF/MC versus unifocal Multifocal/ Multicentric (%) Unifocal P N patients 6,565 62,326 Premenopausal 15 5.3 0.003 Postmenopausal 23 12 unknown 62 82 Histology Ductal 55 0.006 Lobular 8.5 0.2 Mixed 0.5 4.1 OTHER 36 41 Tumour size T1 29 31 <0.001 T2 16 17 T3 28 1.9 T4 0.3 Unknown 27 50 MF/MC versus unifocal Vera-Badillo et al Effect of multifocality and multicentricity on outcome in early stage breast cancer. BCRT. 2014

MF/MC versus unifocal Vera-Badillo et al Effect of multifocality and multicentricity on outcome in early stage breast cancer. BCRT. 2014 Treatment modality Multifocal/ Multicentric (%) Unifocal P Breast Conserving Surgery 26 54 <0.001 Chemotherapy 20 Radiotherapy 11 6.9 Hormone therapy 30 27

MF/MC versus unifocal Conclusion “Multifocality appears to be associated with a worse prognosis, however, substantial inter-study heterogeneity limits the precise determination of increased risk. Further validation of the independent prognostic impact of multifocality is warranted” Vera-Badillo et al Effect of multifocality and multicentricity on outcome in early stage breast cancer. BCRT. 2014

Netherlands Cancer Institute (NKI-AVL) 1980-2008 BCT RADIOTHERAPY (RT) IN THE NKI-AVL

Increased use of adjuvant systemic therapy NKI –AVL, 1988-2008 1980-1987 1988-1998 1999-2008 SYSTEMIC THERAPY 203 (19%) 1479 (41%) 1959 (51%) HORMONAL 35 (3%) 1031 (28%) 1510 (40%) CHEMOTHERAPY 172 (16%) 557 (15%) 1138 (30%) Node-negative patienys 11 (6%) 292 (22%) 615 (36%)

Netherlands Cancer Institute (NKI-AVL) 417 patients with local recurrence (LR) 5 yrs LR-rate: 2% 10 yrs LR-rate: 5%

Data now online: Ann Surg Oncol – 2/2015 – open access The Breast (in press) mahdi@rezai.org European Breast Center Duesseldorf Luisen hospital /Germany

tumor size histopathology grading intrinsic subtype Oncoplastic Study (Rezai M- Kern P), n= 1035, 2004-2009, (follow-up: 5,2 years) Analysis of recurrence according to ... tumor size histopathology grading intrinsic subtype age surgical technique European Breast Center Duesseldorf Luisen hospital /Germany

tumor location surgical technique resection volume age Oncoplastic Study (Rezai, Kern), n= 1035, 2004-2009, (follow-up: 5,2 years) Analysis of aesthetic result and pat.satisfaction according to tumor location surgical technique resection volume age BMI mahdi@rezai.org European Breast Center Duesseldorf Luisen hospital /Germany

Cohort: n= 1035 patients, eligible for analysis: n= 944 patients Age at diagnosis (average): 57.6 years (median 58 years) Rezai M- Kern P- Annals Surgical of oncology 2015

Outcome (Recurrence) in the cohort Out of 944 patients, 38 experienced a recurrence  5-years-recurrence rate 4,0% recurrence rate in correlation with the age at time of surgery: < 40 years: 8,3% 40-49 years: 4,8% 50-59 years: 3,1% 60-69 years: 3,9% > 70 years: 3,6% Rezai M- Kern P- Annals Surgical of oncology 2015

Recurrence rate – correlated with histopathology Non-invasive lesions had the highest recurrence rate  DCIS: 6,7% Ductal invasive and lobular histology did not differ in recurrence rate  invasiv-duktal: 3,5%  invasiv-lobulär: 3,6% no difference in outcome – ductal or lobular histology! Rezai M- Kern P- Annals Surgical of oncology 2015

Margin status and re-excision-rate   11.4% (108/944) with unclear margins at 1st surgery 10.2% (11/108) of patients did not undergo a re-excision. No recurrence were seen in these patients at 5,2 years.   . Rezai M- Kern P- Annals Surgical of oncology 2015

Oncoplastic techniques European Breast Center Duesseldorf Luisen hospital /Germany 28 Brustzentrum Düsseldorf Luisenkrankenhaus– Rezai M/Kellersmann S/Knispel S/Kern P

Oncoplastic Surgery Combining lumpectomy or quadrantectomy with local or regional tissue rearrangement so that the breast should be conserved and reshaped to avoid significant deformity

Five major principles of Oncoplastic techniques GLANDULAR ROTATION DERMO GLANDULAR ROTATION TUMOR ADAPTED REDUCTION MAMMOPLASTY BCT – THORACO EPIGASTRIC FLAP (TEF) BCT – ADVANCEMENT FLAP Rezai M, Veronesi U. Oncoplastic principles in breast surgery. Breast Care 2007;2:277-278 Rezai M- Kern P- Annals Surgical of oncology 2015

mahdi@rezai.org European Breast Center Duesseldorf Luisen hospital /Germany

Glandular Rotation 63.8% © Rezai Rezai M, Veronesi U. Oncoplastic principles in breast surgery. Breast Care 2007;2:277-278

Quadrantectomy

Breast gland reconstruction

Tumor-adapted reduction mammoplasty 20.8% Modified inferior pedicle (M.Rezai) © Rezai Rezai M, Veronesi U. Oncoplastic principles in breast surgery. Breast Care 2007;2:277-278

BCT with advancement flap 4.4% (M.Rezai Rezai M, Veronesi U. Oncoplastic principles in breast surgery. Breast Care 2007;2:277-278

(Tumoradapted Rotation mastopexy 6.7% (M. Rezai) Rezai M, Veronesi U. Oncoplastic principles in breast surgery. Breast Care 2007;2:277-278

Dr S.R.Sahni,2007

Dr S.R.Sahni,2007

BCT Thoraco Epigastric Flap and others 3% © Rezai

5 years overall survival G1: 100% , G2: 95,1 % G3: 90,2 % Rezai M- Kern P- Annals Surgical of oncology 2015

% Overall survival according to intrinsic subtype Histopath. subtyp Number Number of event % Luminal A 592 34 558 94.3% Tripelnegt. 97 18 70 81.4% Lum.B Her2 Posit. 80 9 71 88.8% Lum.B Her2 negat 73 11 62 84.9% Her2 Posit. (non Lum) 54 8 46 85.2% Unknown 48 40 83.3% Total 944 88 856 90.7% mahdi@rezai.org

87 % were satisfied with the surgical outcome Patient reported outcome (PRO): surgical result 87 % were satisfied with the surgical outcome

Choice of oncoplastic technique and DFS Cumulative DFS p=0.166 years DFS did not correlate with the choice of a particular onco- plastic technique(p=0.166) 45 Brustzentrum Düsseldorf Luisenkrankenhaus– Rezai M/Kellersmann S/Knispel S/Kern P

Take HOME Beware of the MRI, use it sensibly MC/MF has worse prognosis: adjuvant systemic therapy Adjuvant systemic therapy reduces LR by half Whole breast RT reduces LR rates by another half

Take HOME Optimal imaging Consider neo-adjuvant chemo and radiation therapy Perform complete excision/s +/- oncoplasty

Surgery is only one sub-step out of multiple steps in breast cancer treatment. Thus, both a diagnostic and an oncological expertise are indispensable and a definite requirement.

ACKNOWLEDGEMENTS Prof Umberto Veronesi Prof Mahdi Rezai Prof Emile Rutgers

THANK YOU Dr S.Sahni Senior Consultant Breast Surgeon Indraprastha Apollo Hospital New Delhi